Validation of NRG oncology/RTOG‐0129 risk groups for HPV‐positive and HPV‐negative oropharyngeal squamous cell cancer: Implications for risk‐based therapeutic intensity trials

Carole Fakhry; Qiang Zhang; Maura L. Gillison; Phuc Felix Nguyen‐Tân; David I. Rosenthal; Randal S. Weber; Louise Lambert; Andy Trotti; William Barrett; Wade L. Thorstad; Sue S. Yom; Stuart J. Wong; John A. Ridge; Shyam Rao; Sharon A. Spencer; A. Fortin; David Raben; Jonathan Harris; Quynh‐Thu Le

doi:10.1002/cncr.32025

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

RTOG-0129 risk groups persisted at 5 years and were reproducible in RTOG-0522. However, there was variability in the estimates. These data underscore the importance of long-term follow-up and appropriate patient selection in therapeutic deintensification trials.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Fakhry et al. (2019) studied this question.

synapsesocial.com/papers/69de9663499d77a496b0bdf7 https://doi.org/10.1002/cncr.32025

View Full Paper

Ask AI

Bookmark

Share

Validation of NRG oncology/RTOG‐0129 risk groups for HPV‐positive and HPV‐negative oropharyngeal squamous cell cancer: Implications for risk‐based therapeutic intensity trials

Ask about this paper

Abstract

Discussion

Cite This Study

Validation of NRG oncology/RTOG‐0129 risk groups for HPV‐positive and HPV‐negative oropharyngeal squamous cell cancer: Implications for risk‐based therapeutic intensity trials

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading